Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6233-6243

  Fridén, Markus ^a,b   Winiwarter, Susanne ^a   Jerndal, Gunilla ^a   Bengtsson, Ola ^a,b   Hong, Wan ^a   Bredberg, Ulf ^a   Hammarlund Udenaes, Margareta ^b   Antonsson, Madeleine ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; AMFEBUTAMONE; AMITRIPTYLINE; ATENOLOL; BACLOFEN; CEFOTAXIME; CODEINE; DELAVIRDINE; DIAZEPAM; DIPHENHYDRAMINE; GABAPENTIN; INDOMETACIN; LAMOTRIGINE; LATAMOXEF; LEVOFLOXACIN; LOPERAMIDE; METHOTREXATE; METOPROLOL; MORPHINE; NADOLOL; NELFINAVIR; NITROFURANTOIN; NORFLOXACIN; OXPRENOLOL; OXYCODONE; OXYMORPHONE; PACLITAXEL; PINDOLOL; PROPRANOLOL; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; COMPUTER MODEL; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG STRUCTURE; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; INTERSTITIAL FLUID; LIPOPHILICITY; MALE; NONHUMAN; SCORING SYSTEM;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; EXTRACELLULAR FLUID; HUMANS; LINEAR MODELS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70350054854     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901036q     Document Type: Article

References (50)

1. Bostrom, E.; Simonsson, U.; Hammarlund-Udenaes, M. In vivo blood - brain barrier transport of oxycodone in the rat: indications of active influx and implications for PK/PD. Drug Metab. Dispos. 2006, 34, 1624-1631.
2. Hammarlund-Udenaes, M.; Friden, M.; Syvanen, S.; Gupta, A.On the rate and extent of drug delivery to the brain. Pharm. Res. 2008, 25, 1737-1750.
3. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16, 1514-1519.
4. Norinder, U.; Haeberlein, M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Delivery Rev. 2002, 54, 291-313.
5. Seelig, A.; Gottschlich, R.; Devant, R. M. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 68-72.
6. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Targeting 1998, 6, 151-165.
7. Hammarlund-Udenaes, M.; Bredberg, U.; Friden, M. Methodologies to assess brain drug delivery in lead optimization. Curr. Top. Med. Chem. 2009, 9, 148-162.
8. Pardridge, W. M. Log(BB), PS products and in silico models of drug brain penetration [comment]. Drug Discovery Today 2004, 9, 392-393.
9. Mano, Y.; Higuchi, S.; Kamimura, H. Investigation of the high partition ofYM992, a novel antidepressant, in rat brain: in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm. Drug Dispos. 2002, 23, 351-360.
10. Kalvass, J. C.; Maurer, T. S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos. 2002, 23, 327-338.
11. Friden,M.; Ducrozet, F.; Antonsson,M.;Middleton, B.; Bredberg, U.; Hammarlund-Udenaes, M. Development of a high-throughput brain slice method for studying drug distribution in the CNS. Drug Metab. Dispos. 2009, 37, 1226.
12. Friden,M.;Gupta, A.;Antonsson,M.; Bredberg,U.;Hammarlund-Udenaes, M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab. Dispos. 2007, 35, 1711-1719.
13. Becker, S.; Liu, X. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab. Dispos. 2006, 34, 855-861.
14. Liu, X.; Chen, C. Strategies to optimize brain penetration in drug discovery. Curr. Opin. Drug Discovery Dev. 2005, 8, 505-512.
15. Kalvass, J. C.; Maurer, T. S.; Pollack, G. M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. DrugMetab. Dispos. 2007, 35, 660-666.
16. Kalvass, J. C.; Olson, E. R.; Pollack, G. M. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. Drug Metab. Dispos. 2007, 35, 455-459.
17. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab. Dispos. 2006, 34, 1443-1447.
18. Summerfield, S. G.; Read, K.; Begley, D. J.; Obradovic, T.; Hidalgo, I. J.; Coggon, S.; Lewis, A. V.; Porter, R. A.; Jeffrey, P. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 2007, 322, 205-213.
19. Summerfield, S. G.; Stevens, A. J.; Cutler, L.; del Carmen Osuna, M.; Hammond, B.; Tang, S. P.; Hersey, A.; Spalding,D. J.; Jeffrey, P. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 2006, 316, 1282-1290.
20. Maurer, T. S.; Debartolo,D. B.; Tess, D. A.; Scott, D. O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab. Dispos. 2005, 33, 175-181.
21. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.;Gibbs, J. P.; Gibbs, M.A.;Hatch,H.; Hop,C. E.;Kasman, I. N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F.M.;Nelson, F.; Olson, E.; Rahematpura, S.; Raunig,D.; Rogers, S.; Schmidt,K.; Spracklin, D. K.; Szewc,M.; Troutman,M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using theMDR1A/1Bknockout mouse model. Drug Metab. Dispos. 2005, 33, 165-174.
22. Shen, D. D.; Artru, A. A.; Adkison, K. K. Principles and applicability of CSF sampling for the assessment ofCNS drug delivery and pharmacodynamics. Adv. Drug Delivery Rev. 2004, 56, 1825-1857.
23. Skold, C.; Winiwarter, S.; Wernevik, J.; Bergstrom, F.; Engstrom, L.; Allen,R.; Box, K.; Comer, J.;Mole, J.; Hallberg,A.; Lennernas, H.; Lundstedt, T.; Ungell, A. L.; Karlen, A. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. J. Med. Chem. 2006, 49, 6660-6671.
24. SIMCA P+, version 11.5; Umetrics, AB (Box 7960, SE-90717 Umeå, Sweden), 2006.
25. Wan, H.; Rehngren,M. High-throughput screening of protein binding by equilibriumdialysis combined with liquid chromatography and mass spectrometry. J. Chromatogr., A 2006, 1102, 125-134.
26. Friden,M.;Ljungqvist,H.;Middleton,B.;Bredberg,U.;Hammarlund-Udenaes, M. Improved measurement of drug exposure in brain using drug-specific correction for residual blood. J.Cereb. Blood Flow Metab., in press.
27. Crowe, A.; Morgan, E. H. Iron and transferrin uptake by brain and cerebrospinal fluid in the rat. Brain Res. 1992, 592, 8-16.
28. Habgood, M. D.; Sedgwick, J. E.; Dziegielewska, K. M.; Saunders, N. R. A developmentally regulated blood-cerebrospinal fluid transfer mechanism for albumin in immature rats. J. Physiol. 1992, 456, 181-192.
29. Wan, H.; Holmen, A. G.; Wang, Y.; Lindberg, W.; Englund, M.; Nagard, M. B.; Thompson, R. A. High-throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17, 2639-2648.
30. Wold, S. Validation of QSAR's. Quant. Struct.-Act. Relat. 1991, 10, 191-193.
31. TP-search. www.tp-search.jp.
32. Hsiao,P.;Bui,T.;Ho,R. J.;Unadkat, J.D. Invitro-to-invivoprediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. DrugMetab. Dispos. 2008, 36, 481-484.
33. Fagerholm, U. The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discovery Today 2007, 12, 1076-1082. (Pubitemid 350186133)
34. Seelig, A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 1998, 251, 252-261.
35. Seelig, A.; Landwojtowicz, E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci. 2000, 12, 31-40.
36. Wan, H.; Rehngren, M.; Giordanetto, F.; Bergstrom, F.; Tunek, A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J. Med. Chem. 2007, 50, 4606-4615.
37. Danhof, M.; Levy, G. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther. 1984, 229, 44-50.
38. de Lange, E. C.; Danhof, M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin. Pharmacokinet. 2002, 41, 691-703.
39. Lin, J. H. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr. Drug Metab. 2008, 9, 46-59.
40. Kusuhara, H.; Sugiyama, Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discovery Today 2001, 6, 150-156. (Pubitemid 32098289)
41. Sugiyama, Y.; Kusuhara, H.; Suzuki, H. Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the bloodbrain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J. Controlled Release 1999, 62, 179-186.
42. Rao, V. V.; Dahlheimer, J. L.; Bardgett, M. E.; Snyder, A. Z.; Finch, R. A.; Sartorelli, A. C.; Piwnica-Worms, D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 3900-3905.
43. Okura, T.; Hattori, A.; Takano, Y.; Sato, T.; Hammarlund-Udenaes, M.; Terasaki, T.; Deguchi, Y. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab. Dispos. 2008, 36, 2005-2013.
44. Syvanen, S.; Lindhe, O.; Palner, M.; Kornum, B. R.; Rahman, O.; Langstrom, B.; Knudsen, G. M.; Hammarlund-Udenaes, M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab. Dispos. 2009, 37, 635-643.
45. Davson, H.; Segal, M. B. Physiology of the CSF and Blood-Brain Barrier; CRC Press: Boca Raton, FL, 1995.
46. Abbott, N. J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 2004, 45, 545-552.
47. Pardridge,W.M. Introduction to theBlood-BrainBarrier;Cambridge University Press: Cambridge, U.K., 1998; pp 1-162.
48. Reiber, H.; Peter, J. B. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J. Neurol. Sci. 2001, 184, 101-122.
49. Neuwelt, E.; Abbott, N. J.; Abrey, L.; Banks, W. A.; Blakley, B.; Davis, T.; Engelhardt, B.; Grammas, P.; Nedergaard, M.; Nutt, J.; Pardridge, W.; Rosenberg, G. A.; Smith, Q.; Drewes, L. R. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008, 7, 84-96.
50. Chiro, G. D.; Hammock, M. K.; Bleyer, W. A. Spinal descent of cerebrospinal fluid in man. Neurology 1976, 26, 1-8.